12 research outputs found

    <i>Cysteine dioxygenase type 1 (CDO1)</i> gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer

    No full text
    <div><p>Background</p><p>Progression of colorectal cancer (CRC) has been explained by genomic abnormalities along with the adenoma-carcinoma sequence theory (ACS). The aim of our study is to elucidate whether the promoter DNA methylation of the cancer-specific methylation gene, <i>cysteine dioxygenase 1</i> (<i>CDO1</i>), contributes to the carcinogenic process in CRC.</p><p>Methods</p><p>The study group comprised 107 patients with CRC who underwent surgical resection and 90 adenomas treated with endoscopic resection in the Kitasato University Hospital in 2000. We analyzed the extent of methylation in each tissue using quantitative TaqMan methylation-specific PCR for <i>CDO1</i>.</p><p>Results</p><p>The methylation level increased along with the ACS process (<i>p</i> < 0.0001), and statistically significant differences were found between normal-appearing mucosa (NAM) and low-grade adenoma (<i>p</i> < 0.0001), and between low-grade adenoma and high-grade adenoma (<i>p</i> = 0.01), but not between high-grade adenoma and cancer with no liver metastasis. Furthermore, primary CRC cancers with liver metastasis harbored significantly higher methylation of <i>CDO1</i> than those without liver metastasis (<i>p</i> = 0.02). As a result, the area under the curve by <i>CDO1</i> promoter methylation was 0.96, 0.80, and 0.67 to discriminate cancer from NAM, low-grade adenoma from NAM, and low-grade adenoma from high-grade adenoma, respectively.</p><p>Conclusions</p><p><i>CDO1</i> methylation accumulates during the ACS process, and consistently contributes to CRC progression.</p></div

    Results of CDO1 immunostaining.

    No full text
    <p>A: IHC score = 0. B: IHC score = 1. C: IHC score = 2. D: Results of IHC scoring in cancer tissue and NAM are shown. Intense staining was observed in NAM, and less intense staining was seen in cancer tissues. A significant difference in scoring was seen between the groups.</p

    Log-rank plot analysis and Kaplan-Meier survival curves for OS and RFS in CRC patients according to <i>CDO1</i> TaqMeth V.

    No full text
    <p>A, B: Log-rank plot analysis for OS. C: Kaplan-Meier survival curves for OS comparing CRC patients with <i>CDO1</i> TaqMeth V equal to or below 20.5 and those with <i>CDO1</i> TaqMeth V over 20.5. D, E: Log-rank plot analysis for RFS. F: Kaplan-Meier survival curves for RFS comparing CRC patients with <i>CDO1</i> TaqMeth V equal to or below 44.8 and those with <i>CDO1</i> TaqMeth V over 44.8.</p

    Standard light microscopy findings on hematoxylin-eosin-stained specimens of colorectal adenoma (40Ă—, magnification) and ROC curves for distinguishing between the two tissues.

    No full text
    <p>A: mild atypia. B: moderate atypia. C: severe atypia. D: ROC curve of <i>CDO1</i> promoter methylation for distinguishing between cancer tissue and NAM. When the cut-off value was 15.6, the AUC was 0.96, sensitivity was 95%, and specificity was 90%. E: ROC curve for distinguishing between low-grade adenoma and NAM. F: ROC curve for distinguishing between low-grade adenoma and high-grade adenoma.</p

    Patients’ characteristics by pathogen detection (n = 48).

    No full text
    <p>Post ACQ and FeNO levels were measured one month after asthma exacerbation.</p><p>*p < 0.05, Mann-Whitney U test</p><p>†p < 0.05, multiple logistic regression analysis.</p><p>Patients’ characteristics by pathogen detection (n = 48).</p
    corecore